nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolmetin—osteoarthritis—Prednisone—prostate cancer	0.329	1	CpDpCtD
Tolmetin—CXCL8—prostate cancer	0.199	0.483	CbGaD
Tolmetin—MPO—prostate cancer	0.155	0.376	CbGaD
Tolmetin—PTGS2—prostate cancer	0.0581	0.141	CbGaD
Tolmetin—SLC22A6—Conjugated Estrogens—prostate cancer	0.0177	0.412	CbGbCtD
Tolmetin—PTGS2—Etoposide—prostate cancer	0.0137	0.319	CbGbCtD
Tolmetin—PTGS1—Etoposide—prostate cancer	0.0116	0.269	CbGbCtD
Tolmetin—CXCL8—prostate gland—prostate cancer	0.00205	0.134	CbGeAlD
Tolmetin—CXCL8—urethra—prostate cancer	0.00137	0.0895	CbGeAlD
Tolmetin—TDO2—lymph node—prostate cancer	0.00119	0.0775	CbGeAlD
Tolmetin—CXCL8—bone marrow—prostate cancer	0.00106	0.0689	CbGeAlD
Tolmetin—CXCL8—testis—prostate cancer	0.000902	0.0589	CbGeAlD
Tolmetin—MPO—epithelium—prostate cancer	0.00088	0.0575	CbGeAlD
Tolmetin—MPO—renal system—prostate cancer	0.000816	0.0533	CbGeAlD
Tolmetin—Tolcapone—COMT—prostate cancer	0.000798	0.225	CrCbGaD
Tolmetin—CXCL8—lymph node—prostate cancer	0.000654	0.0427	CbGeAlD
Tolmetin—MPO—bone marrow—prostate cancer	0.000617	0.0403	CbGeAlD
Tolmetin—PTGS1—prostate gland—prostate cancer	0.000568	0.0371	CbGeAlD
Tolmetin—PTGS2—prostate gland—prostate cancer	0.000543	0.0355	CbGeAlD
Tolmetin—MPO—testis—prostate cancer	0.000527	0.0344	CbGeAlD
Tolmetin—PTGS1—seminal vesicle—prostate cancer	0.00048	0.0314	CbGeAlD
Tolmetin—PTGS2—seminal vesicle—prostate cancer	0.000459	0.03	CbGeAlD
Tolmetin—PTGS1—epithelium—prostate cancer	0.000417	0.0273	CbGeAlD
Tolmetin—PTGS2—epithelium—prostate cancer	0.000399	0.0261	CbGeAlD
Tolmetin—PTGS1—renal system—prostate cancer	0.000387	0.0253	CbGeAlD
Tolmetin—MPO—lymph node—prostate cancer	0.000382	0.025	CbGeAlD
Tolmetin—Zolpidem—CYP3A5—prostate cancer	0.000375	0.106	CrCbGaD
Tolmetin—PTGS2—renal system—prostate cancer	0.00037	0.0242	CbGeAlD
Tolmetin—PTGS2—urethra—prostate cancer	0.000364	0.0237	CbGeAlD
Tolmetin—Indomethacin—AKR1C3—prostate cancer	0.000331	0.0933	CrCbGaD
Tolmetin—Indomethacin—PPARA—prostate cancer	0.000287	0.0809	CrCbGaD
Tolmetin—PTGS2—bone marrow—prostate cancer	0.00028	0.0183	CbGeAlD
Tolmetin—Zolpidem—CYP2C19—prostate cancer	0.000255	0.0719	CrCbGaD
Tolmetin—PTGS1—testis—prostate cancer	0.00025	0.0163	CbGeAlD
Tolmetin—Indomethacin—CXCL8—prostate cancer	0.000199	0.0561	CrCbGaD
Tolmetin—Lumiracoxib—CYP2C19—prostate cancer	0.000193	0.0545	CrCbGaD
Tolmetin—Aminohippurate—SLC22A1—prostate cancer	0.000185	0.0521	CrCbGaD
Tolmetin—PTGS1—lymph node—prostate cancer	0.000181	0.0118	CbGeAlD
Tolmetin—PTGS2—lymph node—prostate cancer	0.000173	0.0113	CbGeAlD
Tolmetin—Zolpidem—CYP3A4—prostate cancer	0.000162	0.0457	CrCbGaD
Tolmetin—Glossitis—Doxorubicin—prostate cancer	0.000161	0.00163	CcSEcCtD
Tolmetin—Urticaria—Ethinyl Estradiol—prostate cancer	0.00016	0.00162	CcSEcCtD
Tolmetin—Body temperature increased—Ethinyl Estradiol—prostate cancer	0.000159	0.00161	CcSEcCtD
Tolmetin—Abdominal pain—Ethinyl Estradiol—prostate cancer	0.000159	0.00161	CcSEcCtD
Tolmetin—Flatulence—Estradiol—prostate cancer	0.000159	0.00161	CcSEcCtD
Tolmetin—Dizziness—Bicalutamide—prostate cancer	0.000158	0.0016	CcSEcCtD
Tolmetin—Renal failure—Etoposide—prostate cancer	0.000157	0.00159	CcSEcCtD
Tolmetin—Stomatitis—Etoposide—prostate cancer	0.000156	0.00158	CcSEcCtD
Tolmetin—Toxic epidermal necrolysis—Docetaxel—prostate cancer	0.000155	0.00157	CcSEcCtD
Tolmetin—Purpura—Prednisone—prostate cancer	0.000154	0.00156	CcSEcCtD
Tolmetin—Vomiting—Bicalutamide—prostate cancer	0.000152	0.00153	CcSEcCtD
Tolmetin—Blood urea increased—Epirubicin—prostate cancer	0.000151	0.00153	CcSEcCtD
Tolmetin—Toxic epidermal necrolysis—Capecitabine—prostate cancer	0.00015	0.00152	CcSEcCtD
Tolmetin—Headache—Bicalutamide—prostate cancer	0.00015	0.00151	CcSEcCtD
Tolmetin—Agranulocytosis—Etoposide—prostate cancer	0.000149	0.00151	CcSEcCtD
Tolmetin—Gastrointestinal haemorrhage—Prednisone—prostate cancer	0.000149	0.0015	CcSEcCtD
Tolmetin—Gastritis—Capecitabine—prostate cancer	0.000148	0.00149	CcSEcCtD
Tolmetin—Somnolence—Goserelin—prostate cancer	0.000148	0.00149	CcSEcCtD
Tolmetin—Ketorolac—PTGS2—prostate cancer	0.000148	0.0416	CrCbGaD
Tolmetin—Somnolence—Conjugated Estrogens—prostate cancer	0.000146	0.00148	CcSEcCtD
Tolmetin—Dyspepsia—Goserelin—prostate cancer	0.000146	0.00148	CcSEcCtD
Tolmetin—Dyspepsia—Conjugated Estrogens—prostate cancer	0.000145	0.00146	CcSEcCtD
Tolmetin—Asthenia—Ethinyl Estradiol—prostate cancer	0.000145	0.00146	CcSEcCtD
Tolmetin—Constipation—Goserelin—prostate cancer	0.000142	0.00144	CcSEcCtD
Tolmetin—Nausea—Bicalutamide—prostate cancer	0.000142	0.00143	CcSEcCtD
Tolmetin—Bromfenac—PTGS2—prostate cancer	0.000141	0.0399	CrCbGaD
Tolmetin—Constipation—Conjugated Estrogens—prostate cancer	0.000141	0.00142	CcSEcCtD
Tolmetin—Blood urea increased—Doxorubicin—prostate cancer	0.00014	0.00142	CcSEcCtD
Tolmetin—Abdominal discomfort—Capecitabine—prostate cancer	0.000138	0.0014	CcSEcCtD
Tolmetin—Diarrhoea—Ethinyl Estradiol—prostate cancer	0.000138	0.0014	CcSEcCtD
Tolmetin—Chest pain—Estradiol—prostate cancer	0.000137	0.00139	CcSEcCtD
Tolmetin—Lymphadenopathy—Epirubicin—prostate cancer	0.000136	0.00138	CcSEcCtD
Tolmetin—Gastrointestinal pain—Goserelin—prostate cancer	0.000136	0.00137	CcSEcCtD
Tolmetin—Erythema multiforme—Etoposide—prostate cancer	0.000136	0.00137	CcSEcCtD
Tolmetin—Weight increased—Docetaxel—prostate cancer	0.000136	0.00137	CcSEcCtD
Tolmetin—Dysuria—Capecitabine—prostate cancer	0.000135	0.00136	CcSEcCtD
Tolmetin—Weight decreased—Docetaxel—prostate cancer	0.000135	0.00136	CcSEcCtD
Tolmetin—Gastrointestinal pain—Conjugated Estrogens—prostate cancer	0.000134	0.00136	CcSEcCtD
Tolmetin—Dizziness—Ethinyl Estradiol—prostate cancer	0.000133	0.00135	CcSEcCtD
Tolmetin—Urticaria—Goserelin—prostate cancer	0.000132	0.00133	CcSEcCtD
Tolmetin—Oedema—Estradiol—prostate cancer	0.000132	0.00133	CcSEcCtD
Tolmetin—Anaphylactic shock—Estradiol—prostate cancer	0.000132	0.00133	CcSEcCtD
Tolmetin—Weight increased—Capecitabine—prostate cancer	0.000131	0.00133	CcSEcCtD
Tolmetin—Abdominal pain—Goserelin—prostate cancer	0.000131	0.00133	CcSEcCtD
Tolmetin—Body temperature increased—Goserelin—prostate cancer	0.000131	0.00133	CcSEcCtD
Tolmetin—Renal failure—Docetaxel—prostate cancer	0.000131	0.00132	CcSEcCtD
Tolmetin—Urticaria—Conjugated Estrogens—prostate cancer	0.000131	0.00132	CcSEcCtD
Tolmetin—Weight decreased—Capecitabine—prostate cancer	0.000131	0.00132	CcSEcCtD
Tolmetin—Vascular purpura—Epirubicin—prostate cancer	0.00013	0.00132	CcSEcCtD
Tolmetin—Body temperature increased—Conjugated Estrogens—prostate cancer	0.00013	0.00131	CcSEcCtD
Tolmetin—Abdominal pain—Conjugated Estrogens—prostate cancer	0.00013	0.00131	CcSEcCtD
Tolmetin—Stomatitis—Docetaxel—prostate cancer	0.00013	0.00131	CcSEcCtD
Tolmetin—Cardiac failure congestive—Epirubicin—prostate cancer	0.000128	0.0013	CcSEcCtD
Tolmetin—Vomiting—Ethinyl Estradiol—prostate cancer	0.000128	0.0013	CcSEcCtD
Tolmetin—Chest pain—Mitoxantrone—prostate cancer	0.000128	0.00129	CcSEcCtD
Tolmetin—Renal failure—Capecitabine—prostate cancer	0.000127	0.00128	CcSEcCtD
Tolmetin—Headache—Ethinyl Estradiol—prostate cancer	0.000126	0.00128	CcSEcCtD
Tolmetin—Lymphadenopathy—Doxorubicin—prostate cancer	0.000126	0.00128	CcSEcCtD
Tolmetin—Stomatitis—Capecitabine—prostate cancer	0.000125	0.00127	CcSEcCtD
Tolmetin—Epistaxis—Docetaxel—prostate cancer	0.000125	0.00127	CcSEcCtD
Tolmetin—Urinary tract infection—Capecitabine—prostate cancer	0.000125	0.00127	CcSEcCtD
Tolmetin—Agranulocytosis—Docetaxel—prostate cancer	0.000124	0.00125	CcSEcCtD
Tolmetin—Haematuria—Capecitabine—prostate cancer	0.000123	0.00124	CcSEcCtD
Tolmetin—Oedema—Mitoxantrone—prostate cancer	0.000123	0.00124	CcSEcCtD
Tolmetin—Anaphylactic shock—Mitoxantrone—prostate cancer	0.000123	0.00124	CcSEcCtD
Tolmetin—Epistaxis—Capecitabine—prostate cancer	0.000121	0.00123	CcSEcCtD
Tolmetin—Purpura—Epirubicin—prostate cancer	0.000121	0.00122	CcSEcCtD
Tolmetin—Vascular purpura—Doxorubicin—prostate cancer	0.00012	0.00122	CcSEcCtD
Tolmetin—Lumiracoxib—PTGS2—prostate cancer	0.00012	0.0339	CrCbGaD
Tolmetin—Anaphylactoid reaction—Epirubicin—prostate cancer	0.00012	0.00122	CcSEcCtD
Tolmetin—Agranulocytosis—Capecitabine—prostate cancer	0.00012	0.00121	CcSEcCtD
Tolmetin—Thrombocytopenia—Mitoxantrone—prostate cancer	0.00012	0.00121	CcSEcCtD
Tolmetin—Nausea—Ethinyl Estradiol—prostate cancer	0.00012	0.00121	CcSEcCtD
Tolmetin—Hepatitis—Docetaxel—prostate cancer	0.000119	0.00121	CcSEcCtD
Tolmetin—Asthenia—Goserelin—prostate cancer	0.000119	0.0012	CcSEcCtD
Tolmetin—Cardiac failure congestive—Doxorubicin—prostate cancer	0.000119	0.0012	CcSEcCtD
Tolmetin—Asthenia—Conjugated Estrogens—prostate cancer	0.000118	0.00119	CcSEcCtD
Tolmetin—Somnolence—Estradiol—prostate cancer	0.000117	0.00118	CcSEcCtD
Tolmetin—Weight increased—Prednisone—prostate cancer	0.000117	0.00118	CcSEcCtD
Tolmetin—Gastrointestinal haemorrhage—Epirubicin—prostate cancer	0.000116	0.00118	CcSEcCtD
Tolmetin—Weight decreased—Prednisone—prostate cancer	0.000116	0.00118	CcSEcCtD
Tolmetin—Dyspepsia—Estradiol—prostate cancer	0.000116	0.00117	CcSEcCtD
Tolmetin—Hepatitis—Capecitabine—prostate cancer	0.000116	0.00117	CcSEcCtD
Tolmetin—Visual impairment—Docetaxel—prostate cancer	0.000115	0.00116	CcSEcCtD
Tolmetin—Diarrhoea—Goserelin—prostate cancer	0.000114	0.00115	CcSEcCtD
Tolmetin—Erythema multiforme—Docetaxel—prostate cancer	0.000113	0.00114	CcSEcCtD
Tolmetin—Constipation—Estradiol—prostate cancer	0.000113	0.00114	CcSEcCtD
Tolmetin—Diarrhoea—Conjugated Estrogens—prostate cancer	0.000113	0.00114	CcSEcCtD
Tolmetin—Purpura—Doxorubicin—prostate cancer	0.000112	0.00113	CcSEcCtD
Tolmetin—Visual impairment—Capecitabine—prostate cancer	0.000111	0.00113	CcSEcCtD
Tolmetin—Anaphylactoid reaction—Doxorubicin—prostate cancer	0.000111	0.00112	CcSEcCtD
Tolmetin—Dizziness—Goserelin—prostate cancer	0.00011	0.00111	CcSEcCtD
Tolmetin—Fenbufen—PTGS2—prostate cancer	0.000109	0.0309	CrCbGaD
Tolmetin—Erythema multiforme—Capecitabine—prostate cancer	0.000109	0.0011	CcSEcCtD
Tolmetin—Somnolence—Mitoxantrone—prostate cancer	0.000109	0.0011	CcSEcCtD
Tolmetin—Dizziness—Conjugated Estrogens—prostate cancer	0.000109	0.0011	CcSEcCtD
Tolmetin—Dyspepsia—Mitoxantrone—prostate cancer	0.000108	0.00109	CcSEcCtD
Tolmetin—Tinnitus—Capecitabine—prostate cancer	0.000108	0.00109	CcSEcCtD
Tolmetin—Gastrointestinal haemorrhage—Doxorubicin—prostate cancer	0.000108	0.00109	CcSEcCtD
Tolmetin—Gastrointestinal pain—Estradiol—prostate cancer	0.000108	0.00109	CcSEcCtD
Tolmetin—Chest pain—Etoposide—prostate cancer	0.000106	0.00108	CcSEcCtD
Tolmetin—Vomiting—Goserelin—prostate cancer	0.000106	0.00107	CcSEcCtD
Tolmetin—Constipation—Mitoxantrone—prostate cancer	0.000105	0.00106	CcSEcCtD
Tolmetin—Toxic epidermal necrolysis—Epirubicin—prostate cancer	0.000105	0.00106	CcSEcCtD
Tolmetin—Vomiting—Conjugated Estrogens—prostate cancer	0.000105	0.00106	CcSEcCtD
Tolmetin—Urticaria—Estradiol—prostate cancer	0.000105	0.00106	CcSEcCtD
Tolmetin—Abdominal pain—Estradiol—prostate cancer	0.000104	0.00105	CcSEcCtD
Tolmetin—Body temperature increased—Estradiol—prostate cancer	0.000104	0.00105	CcSEcCtD
Tolmetin—Headache—Goserelin—prostate cancer	0.000104	0.00105	CcSEcCtD
Tolmetin—Headache—Conjugated Estrogens—prostate cancer	0.000103	0.00104	CcSEcCtD
Tolmetin—Gastritis—Epirubicin—prostate cancer	0.000103	0.00104	CcSEcCtD
Tolmetin—Anaphylactic shock—Etoposide—prostate cancer	0.000102	0.00103	CcSEcCtD
Tolmetin—Gastrointestinal pain—Mitoxantrone—prostate cancer	0.0001	0.00101	CcSEcCtD
Tolmetin—Thrombocytopenia—Etoposide—prostate cancer	9.99e-05	0.00101	CcSEcCtD
Tolmetin—Flatulence—Capecitabine—prostate cancer	9.91e-05	0.001	CcSEcCtD
Tolmetin—Nausea—Goserelin—prostate cancer	9.86e-05	0.000997	CcSEcCtD
Tolmetin—Nausea—Conjugated Estrogens—prostate cancer	9.77e-05	0.000988	CcSEcCtD
Tolmetin—Urticaria—Mitoxantrone—prostate cancer	9.74e-05	0.000985	CcSEcCtD
Tolmetin—Abdominal pain—Mitoxantrone—prostate cancer	9.69e-05	0.00098	CcSEcCtD
Tolmetin—Body temperature increased—Mitoxantrone—prostate cancer	9.69e-05	0.00098	CcSEcCtD
Tolmetin—Toxic epidermal necrolysis—Doxorubicin—prostate cancer	9.69e-05	0.00098	CcSEcCtD
Tolmetin—Gastritis—Doxorubicin—prostate cancer	9.53e-05	0.000963	CcSEcCtD
Tolmetin—Asthenia—Estradiol—prostate cancer	9.44e-05	0.000955	CcSEcCtD
Tolmetin—Dysuria—Epirubicin—prostate cancer	9.4e-05	0.000951	CcSEcCtD
Tolmetin—Indomethacin—CYP2C19—prostate cancer	9.31e-05	0.0263	CrCbGaD
Tolmetin—Weight increased—Epirubicin—prostate cancer	9.15e-05	0.000925	CcSEcCtD
Tolmetin—Suprofen—PTGS2—prostate cancer	9.12e-05	0.0257	CrCbGaD
Tolmetin—Weight decreased—Epirubicin—prostate cancer	9.1e-05	0.00092	CcSEcCtD
Tolmetin—Somnolence—Etoposide—prostate cancer	9.07e-05	0.000917	CcSEcCtD
Tolmetin—Diarrhoea—Estradiol—prostate cancer	9e-05	0.000911	CcSEcCtD
Tolmetin—Drowsiness—Epirubicin—prostate cancer	8.97e-05	0.000907	CcSEcCtD
Tolmetin—Chest pain—Docetaxel—prostate cancer	8.84e-05	0.000894	CcSEcCtD
Tolmetin—Renal failure—Epirubicin—prostate cancer	8.81e-05	0.000891	CcSEcCtD
Tolmetin—Asthenia—Mitoxantrone—prostate cancer	8.8e-05	0.00089	CcSEcCtD
Tolmetin—Stomatitis—Epirubicin—prostate cancer	8.74e-05	0.000884	CcSEcCtD
Tolmetin—Constipation—Etoposide—prostate cancer	8.72e-05	0.000882	CcSEcCtD
Tolmetin—Urinary tract infection—Epirubicin—prostate cancer	8.71e-05	0.000881	CcSEcCtD
Tolmetin—Dizziness—Estradiol—prostate cancer	8.7e-05	0.00088	CcSEcCtD
Tolmetin—Dysuria—Doxorubicin—prostate cancer	8.7e-05	0.00088	CcSEcCtD
Tolmetin—Chest pain—Capecitabine—prostate cancer	8.56e-05	0.000866	CcSEcCtD
Tolmetin—Haematuria—Epirubicin—prostate cancer	8.55e-05	0.000865	CcSEcCtD
Tolmetin—Oedema—Docetaxel—prostate cancer	8.48e-05	0.000857	CcSEcCtD
Tolmetin—Anaphylactic shock—Docetaxel—prostate cancer	8.48e-05	0.000857	CcSEcCtD
Tolmetin—Weight increased—Doxorubicin—prostate cancer	8.47e-05	0.000856	CcSEcCtD
Tolmetin—Epistaxis—Epirubicin—prostate cancer	8.46e-05	0.000855	CcSEcCtD
Tolmetin—Weight decreased—Doxorubicin—prostate cancer	8.42e-05	0.000851	CcSEcCtD
Tolmetin—Diarrhoea—Mitoxantrone—prostate cancer	8.39e-05	0.000849	CcSEcCtD
Tolmetin—Vomiting—Estradiol—prostate cancer	8.37e-05	0.000846	CcSEcCtD
Tolmetin—Agranulocytosis—Epirubicin—prostate cancer	8.37e-05	0.000846	CcSEcCtD
Tolmetin—Gastrointestinal pain—Etoposide—prostate cancer	8.34e-05	0.000844	CcSEcCtD
Tolmetin—Thrombocytopenia—Docetaxel—prostate cancer	8.3e-05	0.000839	CcSEcCtD
Tolmetin—Drowsiness—Doxorubicin—prostate cancer	8.3e-05	0.000839	CcSEcCtD
Tolmetin—Headache—Estradiol—prostate cancer	8.24e-05	0.000834	CcSEcCtD
Tolmetin—Oedema—Capecitabine—prostate cancer	8.21e-05	0.00083	CcSEcCtD
Tolmetin—Renal failure—Doxorubicin—prostate cancer	8.15e-05	0.000825	CcSEcCtD
Tolmetin—Urticaria—Etoposide—prostate cancer	8.1e-05	0.00082	CcSEcCtD
Tolmetin—Stomatitis—Doxorubicin—prostate cancer	8.09e-05	0.000818	CcSEcCtD
Tolmetin—Body temperature increased—Etoposide—prostate cancer	8.06e-05	0.000816	CcSEcCtD
Tolmetin—Abdominal pain—Etoposide—prostate cancer	8.06e-05	0.000816	CcSEcCtD
Tolmetin—Urinary tract infection—Doxorubicin—prostate cancer	8.06e-05	0.000816	CcSEcCtD
Tolmetin—Hepatitis—Epirubicin—prostate cancer	8.05e-05	0.000814	CcSEcCtD
Tolmetin—Thrombocytopenia—Capecitabine—prostate cancer	8.04e-05	0.000813	CcSEcCtD
Tolmetin—Haematuria—Doxorubicin—prostate cancer	7.91e-05	0.0008	CcSEcCtD
Tolmetin—Epistaxis—Doxorubicin—prostate cancer	7.82e-05	0.000791	CcSEcCtD
Tolmetin—Nausea—Estradiol—prostate cancer	7.82e-05	0.000791	CcSEcCtD
Tolmetin—Vomiting—Mitoxantrone—prostate cancer	7.8e-05	0.000789	CcSEcCtD
Tolmetin—Visual impairment—Epirubicin—prostate cancer	7.76e-05	0.000784	CcSEcCtD
Tolmetin—Agranulocytosis—Doxorubicin—prostate cancer	7.74e-05	0.000783	CcSEcCtD
Tolmetin—Headache—Mitoxantrone—prostate cancer	7.68e-05	0.000777	CcSEcCtD
Tolmetin—Erythema multiforme—Epirubicin—prostate cancer	7.61e-05	0.00077	CcSEcCtD
Tolmetin—Somnolence—Docetaxel—prostate cancer	7.54e-05	0.000762	CcSEcCtD
Tolmetin—Tinnitus—Epirubicin—prostate cancer	7.5e-05	0.000759	CcSEcCtD
Tolmetin—Dyspepsia—Docetaxel—prostate cancer	7.46e-05	0.000755	CcSEcCtD
Tolmetin—Hepatitis—Doxorubicin—prostate cancer	7.45e-05	0.000753	CcSEcCtD
Tolmetin—Asthenia—Etoposide—prostate cancer	7.32e-05	0.00074	CcSEcCtD
Tolmetin—Oedema—Prednisone—prostate cancer	7.31e-05	0.000739	CcSEcCtD
Tolmetin—Anaphylactic shock—Prednisone—prostate cancer	7.31e-05	0.000739	CcSEcCtD
Tolmetin—Nausea—Mitoxantrone—prostate cancer	7.28e-05	0.000737	CcSEcCtD
Tolmetin—Constipation—Docetaxel—prostate cancer	7.25e-05	0.000733	CcSEcCtD
Tolmetin—Dyspepsia—Capecitabine—prostate cancer	7.22e-05	0.000731	CcSEcCtD
Tolmetin—Visual impairment—Doxorubicin—prostate cancer	7.18e-05	0.000726	CcSEcCtD
Tolmetin—Erythema multiforme—Doxorubicin—prostate cancer	7.04e-05	0.000712	CcSEcCtD
Tolmetin—Constipation—Capecitabine—prostate cancer	7.02e-05	0.00071	CcSEcCtD
Tolmetin—Diarrhoea—Etoposide—prostate cancer	6.98e-05	0.000706	CcSEcCtD
Tolmetin—Tinnitus—Doxorubicin—prostate cancer	6.94e-05	0.000702	CcSEcCtD
Tolmetin—Gastrointestinal pain—Docetaxel—prostate cancer	6.93e-05	0.000701	CcSEcCtD
Tolmetin—Flatulence—Epirubicin—prostate cancer	6.9e-05	0.000698	CcSEcCtD
Tolmetin—Dizziness—Etoposide—prostate cancer	6.75e-05	0.000682	CcSEcCtD
Tolmetin—Gastrointestinal pain—Capecitabine—prostate cancer	6.71e-05	0.000679	CcSEcCtD
Tolmetin—Abdominal pain—Docetaxel—prostate cancer	6.7e-05	0.000678	CcSEcCtD
Tolmetin—Body temperature increased—Docetaxel—prostate cancer	6.7e-05	0.000678	CcSEcCtD
Tolmetin—Urticaria—Capecitabine—prostate cancer	6.52e-05	0.000659	CcSEcCtD
Tolmetin—Body temperature increased—Capecitabine—prostate cancer	6.49e-05	0.000656	CcSEcCtD
Tolmetin—Abdominal pain—Capecitabine—prostate cancer	6.49e-05	0.000656	CcSEcCtD
Tolmetin—Vomiting—Etoposide—prostate cancer	6.49e-05	0.000656	CcSEcCtD
Tolmetin—Dyspepsia—Prednisone—prostate cancer	6.44e-05	0.000651	CcSEcCtD
Tolmetin—Headache—Etoposide—prostate cancer	6.39e-05	0.000646	CcSEcCtD
Tolmetin—Flatulence—Doxorubicin—prostate cancer	6.39e-05	0.000646	CcSEcCtD
Tolmetin—Constipation—Prednisone—prostate cancer	6.25e-05	0.000632	CcSEcCtD
Tolmetin—Asthenia—Docetaxel—prostate cancer	6.08e-05	0.000615	CcSEcCtD
Tolmetin—Nausea—Etoposide—prostate cancer	6.06e-05	0.000613	CcSEcCtD
Tolmetin—Gastrointestinal pain—Prednisone—prostate cancer	5.98e-05	0.000605	CcSEcCtD
Tolmetin—Chest pain—Epirubicin—prostate cancer	5.96e-05	0.000603	CcSEcCtD
Tolmetin—Asthenia—Capecitabine—prostate cancer	5.89e-05	0.000596	CcSEcCtD
Tolmetin—Urticaria—Prednisone—prostate cancer	5.81e-05	0.000587	CcSEcCtD
Tolmetin—Diarrhoea—Docetaxel—prostate cancer	5.8e-05	0.000587	CcSEcCtD
Tolmetin—Indomethacin—PTGS2—prostate cancer	5.8e-05	0.0163	CrCbGaD
Tolmetin—Body temperature increased—Prednisone—prostate cancer	5.78e-05	0.000585	CcSEcCtD
Tolmetin—Abdominal pain—Prednisone—prostate cancer	5.78e-05	0.000585	CcSEcCtD
Tolmetin—Oedema—Epirubicin—prostate cancer	5.72e-05	0.000578	CcSEcCtD
Tolmetin—Anaphylactic shock—Epirubicin—prostate cancer	5.72e-05	0.000578	CcSEcCtD
Tolmetin—Diarrhoea—Capecitabine—prostate cancer	5.62e-05	0.000568	CcSEcCtD
Tolmetin—Dizziness—Docetaxel—prostate cancer	5.61e-05	0.000567	CcSEcCtD
Tolmetin—Thrombocytopenia—Epirubicin—prostate cancer	5.6e-05	0.000566	CcSEcCtD
Tolmetin—Chest pain—Doxorubicin—prostate cancer	5.52e-05	0.000558	CcSEcCtD
Tolmetin—Dizziness—Capecitabine—prostate cancer	5.43e-05	0.000549	CcSEcCtD
Tolmetin—Vomiting—Docetaxel—prostate cancer	5.39e-05	0.000545	CcSEcCtD
Tolmetin—Headache—Docetaxel—prostate cancer	5.31e-05	0.000537	CcSEcCtD
Tolmetin—Anaphylactic shock—Doxorubicin—prostate cancer	5.29e-05	0.000535	CcSEcCtD
Tolmetin—Oedema—Doxorubicin—prostate cancer	5.29e-05	0.000535	CcSEcCtD
Tolmetin—Asthenia—Prednisone—prostate cancer	5.25e-05	0.000531	CcSEcCtD
Tolmetin—Vomiting—Capecitabine—prostate cancer	5.22e-05	0.000528	CcSEcCtD
Tolmetin—Thrombocytopenia—Doxorubicin—prostate cancer	5.18e-05	0.000524	CcSEcCtD
Tolmetin—Headache—Capecitabine—prostate cancer	5.14e-05	0.00052	CcSEcCtD
Tolmetin—Somnolence—Epirubicin—prostate cancer	5.08e-05	0.000514	CcSEcCtD
Tolmetin—Nausea—Docetaxel—prostate cancer	5.04e-05	0.000509	CcSEcCtD
Tolmetin—Dyspepsia—Epirubicin—prostate cancer	5.03e-05	0.000509	CcSEcCtD
Tolmetin—Diarrhoea—Prednisone—prostate cancer	5e-05	0.000506	CcSEcCtD
Tolmetin—Constipation—Epirubicin—prostate cancer	4.89e-05	0.000495	CcSEcCtD
Tolmetin—Nausea—Capecitabine—prostate cancer	4.88e-05	0.000493	CcSEcCtD
Tolmetin—Dizziness—Prednisone—prostate cancer	4.83e-05	0.000489	CcSEcCtD
Tolmetin—Somnolence—Doxorubicin—prostate cancer	4.7e-05	0.000476	CcSEcCtD
Tolmetin—Gastrointestinal pain—Epirubicin—prostate cancer	4.68e-05	0.000473	CcSEcCtD
Tolmetin—Dyspepsia—Doxorubicin—prostate cancer	4.66e-05	0.000471	CcSEcCtD
Tolmetin—Vomiting—Prednisone—prostate cancer	4.65e-05	0.00047	CcSEcCtD
Tolmetin—Headache—Prednisone—prostate cancer	4.58e-05	0.000463	CcSEcCtD
Tolmetin—Urticaria—Epirubicin—prostate cancer	4.54e-05	0.000459	CcSEcCtD
Tolmetin—Constipation—Doxorubicin—prostate cancer	4.52e-05	0.000458	CcSEcCtD
Tolmetin—Abdominal pain—Epirubicin—prostate cancer	4.52e-05	0.000457	CcSEcCtD
Tolmetin—Body temperature increased—Epirubicin—prostate cancer	4.52e-05	0.000457	CcSEcCtD
Tolmetin—Nausea—Prednisone—prostate cancer	4.34e-05	0.000439	CcSEcCtD
Tolmetin—Gastrointestinal pain—Doxorubicin—prostate cancer	4.33e-05	0.000438	CcSEcCtD
Tolmetin—Urticaria—Doxorubicin—prostate cancer	4.2e-05	0.000425	CcSEcCtD
Tolmetin—Body temperature increased—Doxorubicin—prostate cancer	4.18e-05	0.000423	CcSEcCtD
Tolmetin—Abdominal pain—Doxorubicin—prostate cancer	4.18e-05	0.000423	CcSEcCtD
Tolmetin—Asthenia—Epirubicin—prostate cancer	4.1e-05	0.000415	CcSEcCtD
Tolmetin—Diarrhoea—Epirubicin—prostate cancer	3.91e-05	0.000396	CcSEcCtD
Tolmetin—Asthenia—Doxorubicin—prostate cancer	3.8e-05	0.000384	CcSEcCtD
Tolmetin—Dizziness—Epirubicin—prostate cancer	3.78e-05	0.000382	CcSEcCtD
Tolmetin—Vomiting—Epirubicin—prostate cancer	3.64e-05	0.000368	CcSEcCtD
Tolmetin—Diarrhoea—Doxorubicin—prostate cancer	3.62e-05	0.000366	CcSEcCtD
Tolmetin—Headache—Epirubicin—prostate cancer	3.58e-05	0.000362	CcSEcCtD
Tolmetin—Dizziness—Doxorubicin—prostate cancer	3.5e-05	0.000354	CcSEcCtD
Tolmetin—Nausea—Epirubicin—prostate cancer	3.4e-05	0.000344	CcSEcCtD
Tolmetin—Vomiting—Doxorubicin—prostate cancer	3.36e-05	0.00034	CcSEcCtD
Tolmetin—Headache—Doxorubicin—prostate cancer	3.31e-05	0.000335	CcSEcCtD
Tolmetin—Nausea—Doxorubicin—prostate cancer	3.14e-05	0.000318	CcSEcCtD
Tolmetin—CXCL8—Signaling Pathways—ADRB2—prostate cancer	7.4e-06	7.56e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—NPPA—prostate cancer	7.38e-06	7.54e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—HIST1H4H—prostate cancer	7.38e-06	7.54e-05	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—prostate cancer	7.36e-06	7.52e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—NCOA3—prostate cancer	7.32e-06	7.48e-05	CbGpPWpGaD
Tolmetin—CXCL8—GPCR downstream signaling—JAK2—prostate cancer	7.3e-06	7.46e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism of lipids and lipoproteins—CYP1A1—prostate cancer	7.29e-06	7.45e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—MAP2K1—prostate cancer	7.27e-06	7.43e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—GSTA2—prostate cancer	7.27e-06	7.42e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—PIK3CD—prostate cancer	7.22e-06	7.38e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—VAV3—prostate cancer	7.22e-06	7.37e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	7.19e-06	7.35e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—ABCG5—prostate cancer	7.18e-06	7.33e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—SULT1A1—prostate cancer	7.18e-06	7.33e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—TGFBR2—prostate cancer	7.11e-06	7.27e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—GSTA1—prostate cancer	7.01e-06	7.16e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—ITPR1—prostate cancer	7e-06	7.15e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—HPGDS—prostate cancer	6.98e-06	7.13e-05	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—PIK3CA—prostate cancer	6.96e-06	7.11e-05	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—prostate cancer	6.95e-06	7.1e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—CYP2C19—prostate cancer	6.94e-06	7.09e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—GSTO1—prostate cancer	6.93e-06	7.08e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—NAT2—prostate cancer	6.93e-06	7.08e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—HSD3B2—prostate cancer	6.93e-06	7.08e-05	CbGpPWpGaD
Tolmetin—CXCL8—GPCR downstream signaling—PIK3CB—prostate cancer	6.93e-06	7.08e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—ACHE—prostate cancer	6.77e-06	6.92e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—GSTT1—prostate cancer	6.77e-06	6.92e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—CYP2A6—prostate cancer	6.69e-06	6.84e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—IGF1R—prostate cancer	6.69e-06	6.84e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	6.67e-06	6.81e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	6.67e-06	6.81e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—PLCB2—prostate cancer	6.65e-06	6.79e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—LRP2—prostate cancer	6.65e-06	6.79e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—CYP2C18—prostate cancer	6.65e-06	6.79e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—JAK2—prostate cancer	6.63e-06	6.77e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—P4HB—prostate cancer	6.52e-06	6.66e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—AKR1C3—prostate cancer	6.51e-06	6.65e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—PRKACB—prostate cancer	6.48e-06	6.62e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—LPL—prostate cancer	6.42e-06	6.55e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—CYP17A1—prostate cancer	6.41e-06	6.55e-05	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—prostate cancer	6.39e-06	6.52e-05	CbGpPWpGaD
Tolmetin—CXCL8—GPCR downstream signaling—IL2—prostate cancer	6.37e-06	6.5e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—PDGFRB—prostate cancer	6.36e-06	6.5e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—SLC22A1—prostate cancer	6.34e-06	6.48e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	6.32e-06	6.46e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—PIK3CB—prostate cancer	6.3e-06	6.43e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—B2M—prostate cancer	6.27e-06	6.41e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—TGFBR1—prostate cancer	6.27e-06	6.41e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	6.27e-06	6.4e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—ITGB3—prostate cancer	6.2e-06	6.33e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—SULT2A1—prostate cancer	6.18e-06	6.31e-05	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—prostate cancer	6.18e-06	6.31e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—RPS19—prostate cancer	6.17e-06	6.31e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—AKR1C3—prostate cancer	6.17e-06	6.31e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—PRKACB—prostate cancer	6.14e-06	6.27e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—NCOA2—prostate cancer	6.11e-06	6.24e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—MED12—prostate cancer	6.08e-06	6.21e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—GNG5—prostate cancer	6.03e-06	6.16e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—ERBB3—prostate cancer	6.01e-06	6.14e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—FGFR2—prostate cancer	6e-06	6.13e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—PPP3CA—prostate cancer	5.99e-06	6.11e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—SLC5A5—prostate cancer	5.83e-06	5.95e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—NCOA3—prostate cancer	5.81e-06	5.94e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—PRKCZ—prostate cancer	5.79e-06	5.92e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—IL2—prostate cancer	5.78e-06	5.91e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—TERT—prostate cancer	5.76e-06	5.89e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	5.71e-06	5.83e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—CYP2E1—prostate cancer	5.69e-06	5.81e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—CALR—prostate cancer	5.69e-06	5.81e-05	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—AKT1—prostate cancer	5.69e-06	5.81e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—NQO1—prostate cancer	5.63e-06	5.75e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—FGFR4—prostate cancer	5.59e-06	5.71e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—PARP1—prostate cancer	5.59e-06	5.71e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—TH—prostate cancer	5.55e-06	5.67e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—HPGDS—prostate cancer	5.54e-06	5.66e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—CALCA—prostate cancer	5.52e-06	5.64e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	5.51e-06	5.63e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—HIF1A—prostate cancer	5.51e-06	5.63e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—CYP2C19—prostate cancer	5.51e-06	5.63e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—CYP3A4—prostate cancer	5.49e-06	5.61e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	5.46e-06	5.58e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—CYP1B1—prostate cancer	5.4e-06	5.51e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—LEP—prostate cancer	5.38e-06	5.49e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—GSTT1—prostate cancer	5.38e-06	5.49e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—ACHE—prostate cancer	5.38e-06	5.49e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—CAV1—prostate cancer	5.33e-06	5.44e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—CYP2A6—prostate cancer	5.31e-06	5.43e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—HSPA1A—prostate cancer	5.3e-06	5.41e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	5.29e-06	5.41e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—KDR—prostate cancer	5.27e-06	5.38e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—GGT1—prostate cancer	5.23e-06	5.34e-05	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—prostate cancer	5.22e-06	5.33e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—AKR1C3—prostate cancer	5.17e-06	5.28e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—NCOA1—prostate cancer	5.15e-06	5.26e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—PRKACB—prostate cancer	5.14e-06	5.25e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—ESR1—prostate cancer	5.13e-06	5.25e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—CYP17A1—prostate cancer	5.09e-06	5.2e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—CASP9—prostate cancer	5.08e-06	5.19e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—CYP19A1—prostate cancer	5.07e-06	5.18e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	5.02e-06	5.13e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—BAD—prostate cancer	5.01e-06	5.12e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—PRKCQ—prostate cancer	4.92e-06	5.03e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—RXRA—prostate cancer	4.9e-06	5e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—APC—prostate cancer	4.85e-06	4.96e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—PIK3CG—prostate cancer	4.85e-06	4.96e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—NCOA2—prostate cancer	4.85e-06	4.95e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—IRS1—prostate cancer	4.8e-06	4.9e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—EGF—prostate cancer	4.8e-06	4.9e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	4.76e-06	4.86e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—COMT—prostate cancer	4.72e-06	4.82e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—GSTP1—prostate cancer	4.69e-06	4.8e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—FGF10—prostate cancer	4.68e-06	4.78e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—GSK3B—prostate cancer	4.66e-06	4.76e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—SLC5A5—prostate cancer	4.63e-06	4.73e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—ITPR1—prostate cancer	4.62e-06	4.72e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—INS—prostate cancer	4.59e-06	4.69e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism of lipids and lipoproteins—EP300—prostate cancer	4.54e-06	4.64e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—CYP2E1—prostate cancer	4.52e-06	4.62e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—CREBBP—prostate cancer	4.5e-06	4.6e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—NQO1—prostate cancer	4.47e-06	4.56e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—TGFBR2—prostate cancer	4.45e-06	4.55e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—IGF1—prostate cancer	4.44e-06	4.54e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—EGFR—prostate cancer	4.42e-06	4.52e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—TH—prostate cancer	4.4e-06	4.5e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—ITPR1—prostate cancer	4.38e-06	4.47e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	4.38e-06	4.47e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—TYMS—prostate cancer	4.36e-06	4.46e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—CYP3A4—prostate cancer	4.36e-06	4.45e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—GSTM1—prostate cancer	4.31e-06	4.41e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—MAP2K1—prostate cancer	4.3e-06	4.39e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—CYP1B1—prostate cancer	4.28e-06	4.38e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—PIK3CD—prostate cancer	4.27e-06	4.36e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—LPL—prostate cancer	4.23e-06	4.33e-05	CbGpPWpGaD
Tolmetin—CXCL8—GPCR downstream signaling—PIK3CA—prostate cancer	4.23e-06	4.32e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—SERPINE1—prostate cancer	4.22e-06	4.31e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—KRAS—prostate cancer	4.18e-06	4.27e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—GGT1—prostate cancer	4.15e-06	4.24e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—CYP1A1—prostate cancer	4.09e-06	4.18e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—NCOA1—prostate cancer	4.09e-06	4.17e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—FGF2—prostate cancer	4.09e-06	4.17e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—ERCC2—prostate cancer	4.06e-06	4.14e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—NOS3—prostate cancer	4.03e-06	4.12e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—CYP19A1—prostate cancer	4.03e-06	4.11e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—LPL—prostate cancer	4.01e-06	4.1e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—PDGFRB—prostate cancer	3.98e-06	4.06e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—JAK2—prostate cancer	3.92e-06	4e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—RXRA—prostate cancer	3.89e-06	3.97e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—ERCC2—prostate cancer	3.84e-06	3.93e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—PIK3CA—prostate cancer	3.84e-06	3.92e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—MDM2—prostate cancer	3.82e-06	3.91e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—MTHFR—prostate cancer	3.81e-06	3.89e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	3.78e-06	3.86e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—ERBB2—prostate cancer	3.77e-06	3.85e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—ERBB3—prostate cancer	3.76e-06	3.84e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—FGFR2—prostate cancer	3.75e-06	3.84e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—COMT—prostate cancer	3.74e-06	3.82e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—PPARA—prostate cancer	3.74e-06	3.82e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—GSTP1—prostate cancer	3.73e-06	3.81e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—PIK3CB—prostate cancer	3.72e-06	3.8e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—ITPR1—prostate cancer	3.67e-06	3.75e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—MTHFR—prostate cancer	3.61e-06	3.69e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	3.61e-06	3.68e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—TERT—prostate cancer	3.6e-06	3.68e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—CAV1—prostate cancer	3.52e-06	3.59e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—CDKN1B—prostate cancer	3.49e-06	3.57e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—TYMS—prostate cancer	3.46e-06	3.54e-05	CbGpPWpGaD
Tolmetin—CXCL8—GPCR downstream signaling—AKT1—prostate cancer	3.45e-06	3.53e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—HIF1A—prostate cancer	3.45e-06	3.52e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—GSTM1—prostate cancer	3.42e-06	3.5e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—CASP3—prostate cancer	3.42e-06	3.49e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—IL2—prostate cancer	3.42e-06	3.49e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—IL6—prostate cancer	3.4e-06	3.47e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—LPL—prostate cancer	3.36e-06	3.43e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	3.36e-06	3.43e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—CAV1—prostate cancer	3.33e-06	3.41e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—CCND1—prostate cancer	3.33e-06	3.4e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—CTNNB1—prostate cancer	3.3e-06	3.37e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—CYP1A1—prostate cancer	3.25e-06	3.32e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—MMP9—prostate cancer	3.23e-06	3.3e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—CDKN1A—prostate cancer	3.22e-06	3.29e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—ERCC2—prostate cancer	3.22e-06	3.29e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—PTEN—prostate cancer	3.21e-06	3.28e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—PIK3CG—prostate cancer	3.2e-06	3.27e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—AKT1—prostate cancer	3.14e-06	3.2e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—BAD—prostate cancer	3.14e-06	3.2e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—EP300—prostate cancer	3.06e-06	3.13e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—APC—prostate cancer	3.04e-06	3.1e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—INS—prostate cancer	3.03e-06	3.1e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—MTHFR—prostate cancer	3.03e-06	3.09e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—IRS1—prostate cancer	3e-06	3.07e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—EGF—prostate cancer	3e-06	3.07e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—SRC—prostate cancer	2.98e-06	3.04e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—CREBBP—prostate cancer	2.97e-06	3.03e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—PPARA—prostate cancer	2.97e-06	3.03e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—GSK3B—prostate cancer	2.91e-06	2.98e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—VEGFA—prostate cancer	2.9e-06	2.97e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—STAT3—prostate cancer	2.87e-06	2.94e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—INS—prostate cancer	2.87e-06	2.94e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—PIK3CD—prostate cancer	2.82e-06	2.88e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—CREBBP—prostate cancer	2.82e-06	2.88e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—CAV1—prostate cancer	2.79e-06	2.85e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—MAP2K1—prostate cancer	2.69e-06	2.74e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—MYC—prostate cancer	2.67e-06	2.73e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—PIK3CD—prostate cancer	2.67e-06	2.73e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.67e-06	2.72e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—TGFB1—prostate cancer	2.66e-06	2.72e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—NOS3—prostate cancer	2.66e-06	2.72e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—SERPINE1—prostate cancer	2.64e-06	2.7e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—EGFR—prostate cancer	2.61e-06	2.67e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—FGF2—prostate cancer	2.56e-06	2.61e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—PIK3CG—prostate cancer	2.54e-06	2.6e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—NOS3—prostate cancer	2.52e-06	2.57e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—KRAS—prostate cancer	2.47e-06	2.52e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—PIK3CB—prostate cancer	2.45e-06	2.51e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—JAK2—prostate cancer	2.45e-06	2.5e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—PTGS2—prostate cancer	2.43e-06	2.48e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—INS—prostate cancer	2.41e-06	2.46e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—MDM2—prostate cancer	2.39e-06	2.44e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—CREBBP—prostate cancer	2.36e-06	2.41e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—ERBB2—prostate cancer	2.36e-06	2.41e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—PIK3CB—prostate cancer	2.33e-06	2.38e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—PIK3CA—prostate cancer	2.27e-06	2.32e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—PIK3CD—prostate cancer	2.24e-06	2.28e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—TP53—prostate cancer	2.19e-06	2.24e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—CDKN1B—prostate cancer	2.18e-06	2.23e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—PTEN—prostate cancer	2.12e-06	2.17e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—NOS3—prostate cancer	2.11e-06	2.16e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—CTNNB1—prostate cancer	2.06e-06	2.11e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—EP300—prostate cancer	2.02e-06	2.07e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—CDKN1A—prostate cancer	2.01e-06	2.06e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—PTEN—prostate cancer	2.01e-06	2.05e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—IL6—prostate cancer	2.01e-06	2.05e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—PIK3CB—prostate cancer	1.95e-06	1.99e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—EP300—prostate cancer	1.92e-06	1.96e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—SRC—prostate cancer	1.86e-06	1.9e-05	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—AKT1—prostate cancer	1.85e-06	1.89e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—STAT3—prostate cancer	1.8e-06	1.84e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—PTEN—prostate cancer	1.68e-06	1.72e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—MYC—prostate cancer	1.67e-06	1.71e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—TGFB1—prostate cancer	1.67e-06	1.7e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—EGFR—prostate cancer	1.63e-06	1.67e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—EP300—prostate cancer	1.61e-06	1.64e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—KRAS—prostate cancer	1.54e-06	1.58e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—PIK3CA—prostate cancer	1.5e-06	1.53e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—PIK3CA—prostate cancer	1.42e-06	1.45e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—IL6—prostate cancer	1.26e-06	1.28e-05	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—AKT1—prostate cancer	1.22e-06	1.25e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—PIK3CA—prostate cancer	1.19e-06	1.21e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—AKT1—prostate cancer	1.16e-06	1.18e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—AKT1—prostate cancer	9.7e-07	9.91e-06	CbGpPWpGaD
